Cornelia Eckert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cornelia Eckert has a total of 412 co-authors. Here are the top co-authors by number of shared publications:
- Angelika Eggert
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
21 shared publications - Annabell Szymansky
Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany
21 shared publications - Anton George Henssen
Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
19 shared publications - Hedwig E. Deubzer
Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany
19 shared publications - Johannes Hubertus Schulte
Charité-Universitätsmedizin Berlin 17 Department of Pediatric Oncology/Hematology Berlin, Germany
19 shared publications - Kathy Astrahantseff
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
19 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by American Society of Hematology in Blood
International Cross-Age Consensus Guideline on Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia
Measurable residual disease (MRD) assessment is central to risk stratification, response evaluation, and relapse detection in acute lymphoblastic leukemia (ALL). However, substantial global variability in its methodology and implementation persists. Differences in sampling strategies, detection methods, reporting thresholds, and interpretation criteria hinder cross-trial comparability and clinical standardization. To address this, an international expert panel representing major pediatric and adult study groups and reference laboratories developed consensus recommendations, using a structured current-practices survey followed by a multi-round Delphi process. Consensus was achieved on 38 of 41 statements. Recommendations span three domains: pre-analytical requirements, technical and nomenclature standards, and MRD-based remission and relapse definitions. Bone marrow was endorsed as the reference specimen for MRD assessment, and MRD was prioritized over cytomorphology in cases of discordance. Principles for risk- and actionability-guided late MRD monitoring, confirmation of MRD reappearance, and MRD-informed relapse assessment were also defined. Among the key technical consensus statements, a standardized MRD assay nomenclature was adopted. Areas without consensus-namely, anticoagulant choice for PCR-based MRD, interpretation of isolated BCR::ABL1 reconversion, and the exclusive use of MRD to define remission-highlight ongoing biological and clinical complexity. This guideline, applicable across all ages, provides a practical framework to standardize MRD assessment in ALL and support MRD-guided clinical decision-making.
- 10 November 2026
- Published by American Society of Hematology in Blood
Open AccessInternational Cross-Age Consensus Guideline on Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia
Measurable residual disease (MRD) assessment is central to risk stratification, response evaluation, and relapse detection in acute lymphoblastic leukemia (ALL). However, substantial global variability in its methodology and implementation persists. Differences in sampling strategies, detection methods, reporting thresholds, and interpretation criteria hinder cross-trial comparability and clinical standardization. To address this, an international expert panel representing major pediatric and adult study groups and reference laboratories developed consensus recommendations, using a structured current-practices survey followed by a multi-round Delphi process. Consensus was achieved on 38 of 41 statements. Recommendations span three domains: pre-analytical requirements, technical and nomenclature standards, and MRD-based remission and relapse definitions. Bone marrow was endorsed as the reference specimen for MRD assessment, and MRD was prioritized over cytomorphology in cases of discordance. Principles for risk- and actionability-guided late MRD monitoring, confirmation of MRD reappearance, and MRD-informed relapse assessment were also defined. Among the key technical consensus statements, a standardized MRD assay nomenclature was adopted. Areas without consensus-namely, anticoagulant choice for PCR-based MRD, interpretation of isolated BCR::ABL1 reconversion, and the exclusive use of MRD to define remission-highlight ongoing biological and clinical complexity. This guideline, applicable across all ages, provides a practical framework to standardize MRD assessment in ALL and support MRD-guided clinical decision-making.
- Open Access
- 18 September 2026
- Published by Springer Nature in Cell Death Discovery
Annexin A6 modulates apoptotic priming and BCL-2 dependency in acute lymphoblastic leukaemia
Annexin A6 (ANXA6) is a Ca²⁺-dependent membrane-binding protein involved in cellular signalling and membrane dynamics, yet its role in apoptosis in haematological malignancies remains poorly defined. Here, we identify ANXA6 as a regulator of apoptotic priming and BCL-2 family protein balance. Using BH3 profiling, we show that ANXA6 depletion reduces apoptotic priming in HeLa cells, indicating increased resistance to mitochondrial apoptosis. This phenotype is associated with increased BCL-2 expression and reduced BAK levels and occurs independently of changes in mitochondrial mass or morphology. Mechanistically, ANXA6-deficient HeLa cells display enhanced activation of pro-survival signalling pathways, such as AKT, which are known to modulate the BCL-2 family of proteins, supporting a role for ANXA6 as a negative regulator of pro-survival signalling. In an acute lymphoblastic leukaemia (ALL) model, ANXA6 expression inversely correlates with BCL-2 and positively with pro-apoptotic proteins BAK and BAD expression across cell lines and patient samples. Functionally, ANXA6 depletion reduces apoptotic priming in selected ALL cell models and increases sensitivity to BCL-2 and BCL-xL inhibition. Together, these findings position ANXA6 as a modulator of apoptotic threshold and a potential determinant of BCL-2 dependency and response to BH3 mimetics in ALL.
- 18 September 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessAnnexin A6 modulates apoptotic priming and BCL-2 dependency in acute lymphoblastic leukaemia
Annexin A6 (ANXA6) is a Ca²⁺-dependent membrane-binding protein involved in cellular signalling and membrane dynamics, yet its role in apoptosis in haematological malignancies remains poorly defined. Here, we identify ANXA6 as a regulator of apoptotic priming and BCL-2 family protein balance. Using BH3 profiling, we show that ANXA6 depletion reduces apoptotic priming in HeLa cells, indicating increased resistance to mitochondrial apoptosis. This phenotype is associated with increased BCL-2 expression and reduced BAK levels and occurs independently of changes in mitochondrial mass or morphology. Mechanistically, ANXA6-deficient HeLa cells display enhanced activation of pro-survival signalling pathways, such as AKT, which are known to modulate the BCL-2 family of proteins, supporting a role for ANXA6 as a negative regulator of pro-survival signalling. In an acute lymphoblastic leukaemia (ALL) model, ANXA6 expression inversely correlates with BCL-2 and positively with pro-apoptotic proteins BAK and BAD expression across cell lines and patient samples. Functionally, ANXA6 depletion reduces apoptotic priming in selected ALL cell models and increases sensitivity to BCL-2 and BCL-xL inhibition. Together, these findings position ANXA6 as a modulator of apoptotic threshold and a potential determinant of BCL-2 dependency and response to BH3 mimetics in ALL.
- Open Access
Quantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) breakpoints
Sensitive detection of minimal residual disease (MRD) remains a major unmet need in high-risk neuroblastoma. MYCN amplification, a hallmark of high-risk disease, typically occurs on extrachromosomal DNA (ecDNA), but the potential of ecDNA-associated genomic rearrangements for individualized MRD monitoring has not been fully exploited. Here, we applied neuroblastoma-specific hybrid capture-based panel sequencing to identify patient-unique breakpoints within MYCN amplicons, and used Circle-seq and Nanopore sequencing to resolve the extrachromosomal amplicon structure in representative samples. Analysis of 8 neuroblastoma cell lines and 22 primary tumors identified 69 tumor-specific breakpoints. Those selected for assay development were validated by breakpoint-specific PCR and Sanger sequencing. Breakpoints detected in primary tumors remained detectable at relapse, supporting their stability as MRD markers. Breakpoint-specific real-time quantitative PCR and droplet digital PCR detected these junctions in bone marrow aspirates with high specificity and reached sensitivities down to a tumor DNA fraction of 10^-6. We applied this approach to 53 serial bone marrow aspirates from 14 patients with high-risk neuroblastoma to monitor MRD dynamics, resolving treatment response and molecular persistence. In six samples, breakpoint-positive DNA was detected in bone marrow that was negative by conventional cytology and immunocytology, highlighting the added value of molecular monitoring. Together, these findings establish ecDNA breakpoint-based detection as a strategy for MRD assessment in neuroblastoma, that is, in principle, applicable to any ecDNA-amplified oncogene.
Open AccessQuantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) breakpoints
Sensitive detection of minimal residual disease (MRD) remains a major unmet need in high-risk neuroblastoma. MYCN amplification, a hallmark of high-risk disease, typically occurs on extrachromosomal DNA (ecDNA), but the potential of ecDNA-associated genomic rearrangements for individualized MRD monitoring has not been fully exploited. Here, we applied neuroblastoma-specific hybrid capture-based panel sequencing to identify patient-unique breakpoints within MYCN amplicons, and used Circle-seq and Nanopore sequencing to resolve the extrachromosomal amplicon structure in representative samples. Analysis of 8 neuroblastoma cell lines and 22 primary tumors identified 69 tumor-specific breakpoints. Those selected for assay development were validated by breakpoint-specific PCR and Sanger sequencing. Breakpoints detected in primary tumors remained detectable at relapse, supporting their stability as MRD markers. Breakpoint-specific real-time quantitative PCR and droplet digital PCR detected these junctions in bone marrow aspirates with high specificity and reached sensitivities down to a tumor DNA fraction of 10^-6. We applied this approach to 53 serial bone marrow aspirates from 14 patients with high-risk neuroblastoma to monitor MRD dynamics, resolving treatment response and molecular persistence. In six samples, breakpoint-positive DNA was detected in bone marrow that was negative by conventional cytology and immunocytology, highlighting the added value of molecular monitoring. Together, these findings establish ecDNA breakpoint-based detection as a strategy for MRD assessment in neuroblastoma, that is, in principle, applicable to any ecDNA-amplified oncogene.
- Open Access
- 2 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Molecular variants, clonal evolution and clinical relevance in pediatric and adult T-cell lymphoblastic neoplasia
T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukemia (T-ALL) originate from thymic T-cell precursors, with ongoing debate on whether they are variants of the same disease or distinct entities. For 211 patients, including pediatric and adult T-ALL and T-LBL cases, targeted next-generation sequencing and SNP-arrays were performed, and single-nucleotide variants, indels and copy-number variants (CNVs) were analyzed. We aimed to assess genetic differences between T-ALL and T-LBL across age. Generally, mutational landscape analysis identified mutated PHF6 being associated with higher, NOTCH1 with lower age at diagnosis for both T-LBL and T-ALL. Association of CNVs with higher age was evident for T-ALL, but not T-LBL. Analysis of clonal evolution revealed that CNVs – especially deletions and LOH in chromosome 9 (LOH_in_9p) – were observed as first mutational event in both pediatric T-ALL and T-LBL. The sequence of genetic events, starting with LOH_in_9p followed by mutations in NOTCH1 , was significantly more frequent in pediatric T-ALL and T-LBL. Detailed evaluation of the patients’ individual clonal evolution indicated that the proportion of malignant cells without NOTCH MT determines the risk of relapse (hazard ratio 1.032, p = 4.65*10 −5 ). In T-ALL, aside from MRD, validated molecular markers for risk-group stratification remain limited. Our data suggest that molecular metrics analogous to those in T-LBL may help refining risk stratification in T-ALL as well.
- 2 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessMolecular variants, clonal evolution and clinical relevance in pediatric and adult T-cell lymphoblastic neoplasia
T-cell lymphoblastic lymphoma (T-LBL) and T-cell acute lymphoblastic leukemia (T-ALL) originate from thymic T-cell precursors, with ongoing debate on whether they are variants of the same disease or distinct entities. For 211 patients, including pediatric and adult T-ALL and T-LBL cases, targeted next-generation sequencing and SNP-arrays were performed, and single-nucleotide variants, indels and copy-number variants (CNVs) were analyzed. We aimed to assess genetic differences between T-ALL and T-LBL across age. Generally, mutational landscape analysis identified mutated PHF6 being associated with higher, NOTCH1 with lower age at diagnosis for both T-LBL and T-ALL. Association of CNVs with higher age was evident for T-ALL, but not T-LBL. Analysis of clonal evolution revealed that CNVs – especially deletions and LOH in chromosome 9 (LOH_in_9p) – were observed as first mutational event in both pediatric T-ALL and T-LBL. The sequence of genetic events, starting with LOH_in_9p followed by mutations in NOTCH1 , was significantly more frequent in pediatric T-ALL and T-LBL. Detailed evaluation of the patients’ individual clonal evolution indicated that the proportion of malignant cells without NOTCH MT determines the risk of relapse (hazard ratio 1.032, p = 4.65*10 −5 ). In T-ALL, aside from MRD, validated molecular markers for risk-group stratification remain limited. Our data suggest that molecular metrics analogous to those in T-LBL may help refining risk stratification in T-ALL as well.
- Open Access
- 13 November 2025
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 230-234
Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study
- 13 November 2025
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 230-234
Open AccessBlinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study
- Open Access
- 7 August 2025
- Published by Springer Nature in Nature Methods
- Vol. 22 (9) , 1-13
Ultra-high-scale cytometry-based cellular interaction mapping
Cellular interactions are of fundamental importance, orchestrating organismal development, tissue homeostasis and immunity. Recently, powerful methods that use single-cell genomic technologies to dissect physically interacting cells have been developed. However, these approaches are characterized by low cellular throughput, long processing times and high costs and are typically restricted to predefined cell types. Here we introduce Interact-omics, a cytometry-based framework to accurately map cellular landscapes and cellular interactions across all immune cell types at ultra-high resolution and scale. We demonstrate the utility of our approach to study kinetics, mode of action and personalized response prediction of immunotherapies, and organism-wide shifts in cellular composition and cellular interaction dynamics following infection in vivo. Our scalable framework can be applied a posteriori to existing cytometry datasets or incorporated into newly designed cytometry-based studies to map cellular interactions with a broad range of applications from fundamental biology to applied biomedicine.
- 7 August 2025
- Published by Springer Nature in Nature Methods
- Vol. 22 (9) , 1-13
Open AccessUltra-high-scale cytometry-based cellular interaction mapping
Cellular interactions are of fundamental importance, orchestrating organismal development, tissue homeostasis and immunity. Recently, powerful methods that use single-cell genomic technologies to dissect physically interacting cells have been developed. However, these approaches are characterized by low cellular throughput, long processing times and high costs and are typically restricted to predefined cell types. Here we introduce Interact-omics, a cytometry-based framework to accurately map cellular landscapes and cellular interactions across all immune cell types at ultra-high resolution and scale. We demonstrate the utility of our approach to study kinetics, mode of action and personalized response prediction of immunotherapies, and organism-wide shifts in cellular composition and cellular interaction dynamics following infection in vivo. Our scalable framework can be applied a posteriori to existing cytometry datasets or incorporated into newly designed cytometry-based studies to map cellular interactions with a broad range of applications from fundamental biology to applied biomedicine.
- Open Access
- 27 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia
T-ALL relapses are characterized by chemotherapy resistance, cellular diversity and dismal outcome. To gain a deeper understanding of the mechanisms underlying relapses, we conduct single-cell RNA sequencing on 13 matched pediatric T-ALL patient-derived samples at diagnosis and relapse, along with samples derived from 5 non-relapsing patients collected at diagnosis. This comprehensive longitudinal single-cell study in T-ALL reveals significant transcriptomic diversity. Notably, 11 out of 18 samples exhibit a subpopulation of T-ALL cells with stem-like features characterized by a common set of active regulons, expression patterns and splice isoforms. This subpopulation, accounting for a small proportion of leukemia cells at diagnosis, expands substantially at relapse, indicating resistance to therapy. Strikingly, increased stemness at diagnosis is associated with higher risk of treatment induction failure. Chemotherapy resistance is validated through in-vitro and in-vivo drug testing. Thus, we report the discovery of treatment-resistant stem-like cells in T-ALL, underscoring the potential for devising future therapeutic strategies targeting stemness-related pathways.
- 27 June 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessRole of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia
T-ALL relapses are characterized by chemotherapy resistance, cellular diversity and dismal outcome. To gain a deeper understanding of the mechanisms underlying relapses, we conduct single-cell RNA sequencing on 13 matched pediatric T-ALL patient-derived samples at diagnosis and relapse, along with samples derived from 5 non-relapsing patients collected at diagnosis. This comprehensive longitudinal single-cell study in T-ALL reveals significant transcriptomic diversity. Notably, 11 out of 18 samples exhibit a subpopulation of T-ALL cells with stem-like features characterized by a common set of active regulons, expression patterns and splice isoforms. This subpopulation, accounting for a small proportion of leukemia cells at diagnosis, expands substantially at relapse, indicating resistance to therapy. Strikingly, increased stemness at diagnosis is associated with higher risk of treatment induction failure. Chemotherapy resistance is validated through in-vitro and in-vivo drug testing. Thus, we report the discovery of treatment-resistant stem-like cells in T-ALL, underscoring the potential for devising future therapeutic strategies targeting stemness-related pathways.
- 23 May 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 219,p. e67451
Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
Zebrafish xenotransplantation is a pivotal technique for investigating human cancer pathogenesis and predicting individual drug responses. This document introduces a streamlined protocol (ZefiX) for expanding primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patient samples or immortalized cell lines in transiently immunosuppressed zebrafish embryos, utilizing flow cytometry for high-resolution single-cell analysis of treatment responses. Compared to solid tumor engraftments, leukemia cells profit significantly from a morpholino antisense oligonucleotide-based suppression of macrophage and neutrophil differentiating factors during the assay. Flow cytometry analysis of dissociated graft cells enables precise evaluation of cell count, proliferation rate, and vitality after treatment on a per-cell basis. This approach has been validated using targeted therapeutics such as venetoclax and dasatinib, with treatment outcomes compared to clinical records of related patient samples and traditional 2D culture controls. Notably, the protocol is completed within 7 days, aligning with clinical decision-making timelines. The methodology is adaptable for testing selected drugs in various cancer types, including solid tumors, thereby supporting personalized therapeutic strategies. However, limitations on the number of drugs that can be assessed, likely due to pharmacokinetic constraints in zebrafish embryos, should be considered.
- 23 May 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 219,p. e67451
Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
Zebrafish xenotransplantation is a pivotal technique for investigating human cancer pathogenesis and predicting individual drug responses. This document introduces a streamlined protocol (ZefiX) for expanding primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patient samples or immortalized cell lines in transiently immunosuppressed zebrafish embryos, utilizing flow cytometry for high-resolution single-cell analysis of treatment responses. Compared to solid tumor engraftments, leukemia cells profit significantly from a morpholino antisense oligonucleotide-based suppression of macrophage and neutrophil differentiating factors during the assay. Flow cytometry analysis of dissociated graft cells enables precise evaluation of cell count, proliferation rate, and vitality after treatment on a per-cell basis. This approach has been validated using targeted therapeutics such as venetoclax and dasatinib, with treatment outcomes compared to clinical records of related patient samples and traditional 2D culture controls. Notably, the protocol is completed within 7 days, aligning with clinical decision-making timelines. The methodology is adaptable for testing selected drugs in various cancer types, including solid tumors, thereby supporting personalized therapeutic strategies. However, limitations on the number of drugs that can be assessed, likely due to pharmacokinetic constraints in zebrafish embryos, should be considered.